Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Open accessThe DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
Abstract
Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel lead to recurrent attacks of optic neuritis, myelitis and/or brainstem syndromes. In some patients with symptoms of NMOSD, no AQP4-Abs but Abs against myelin-oligodendrocyte-glycoprotein (MOG) are detectable. These clinical syndromes are now frequently referred to as "MOG-encephalomyelitis" (MOG-EM). Here we give an overview on current recommendations concerning diagnosis of NMOSD and MOG-EM. These include antibody and further laboratory testing, MR imaging and optical coherence tomography. We discuss therapeutic options of acute attacks as well as longterm immunosuppressive treatment, including azathioprine, rituximab, and immunoglobulins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649 · cited 15×
“This can be helpful to diagnose MOG-EM or NMOSD in patients without AQP4-Abs (46, 77, 131, 134, 135).”
BackgroundMethodInfluentialA serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239 · cited 1×
“AQP4-Abs were firstly described in 2004 and made it possible to differentiate NMOSD from MS (78).”
BackgroundRevised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574 · cited 4×
“Brain MRI at first presentation often shows no lesions which has been the reason to define normal brain MRI as one NMO diagnostic criterion in 2006 (116).”
BackgroundMethodInfluentialRuiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899 · cited 10×
“In MOG-EM, approximately 80% of patients with evidence of MOG-Abs during acute attack remained seropositive during remission (33).”
BackgroundResultInfluentialSelf-citationIdentification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850 · cited 3×
“Whereas spinal cord lesions frequently affect cervicothoracic segments in NMOSD, they tend to be localized in thoracolumbar parts of the spinal cord including the conus in MOG-EM (29, 31).”
BackgroundJarius, S., Ruprecht, K., Wildemann, B., Kuempfel, T., Ringelstein, M., Geis, C., Kleiter, I., Kleinschnitz, C., Berthele, A., Brettschneider, J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-14 · Cited by 764 · cited 3×
“In AQP4-Ab positive NMOSD, most patients (80– 90%) have a relapsing disease course (26, 73, 74).”
BackgroundSelf-citationMOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1144-2 · Cited by 747 · cited 16×
“In MOG-EM, approximately 80% of patients with evidence of MOG-Abs during acute attack remained seropositive during remission (33).”
BackgroundResultInfluentialSelf-citationClinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740 · cited 3×
“However, there are indications that MOG-EM has a less severe course than NMOSD and relapse risk depends on Ab status (30, 65, 66).”
BackgroundBrain Abnormalities in Neuromyelitis Optica
Pittock, S. J., Lennon, V. A., Krecke, K., Wingerchuk, D. M., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.390 · Cited by 675
MRI characteristics of neuromyelitis optica spectrum disorder: An international update
Kim, H. J., Paul, F., Lana-Peixoto, M. A., Tenembaum, S., Asgari, N., Palace, J., Klawiter, E. C., Sato, D. K., de Seze, J., Wuerfel, J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001367 · Cited by 664
Self-citationAn open label study of the effects of rituximab in neuromyelitis optica
Cree, B. A. C., Lamb, S., Morgan, K., Chen, A., Waubant, E., & Genain, C. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646 · cited 1×
“In 2005, an open label study described for the first time a significant reduction in disease activity in eight NMO patients treated with RTX (195).”
BackgroundLoss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis
Misu, T., Fujihara, K., Kakita, A., Konno, H., Nakamura, M., Watanabe, S., Takahashi, T., Nakashima, I., Takahashi, H., & Itoyama, Y. (2007) · Brain · doi:10.1093/brain/awm047 · Cited by 614 · cited 1×
“However, while inflammation in MOG-EM primarily results in demyelination, demyelination in NMOSD seems to be a secondary phenomenon following astrocytic damage (61, 62).”
BackgroundNeuromyelitis Optica and Non–Organ-Specific Autoimmunity
Pittock, S. J., Lennon, V. A., de Seze, J., Vermersch, P., Homburger, H. A., Wingerchuk, D. M., Lucchinetti, C. F., Zéphir, H., Moder, K., & Weinshenker, B. G. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.17 · Cited by 608
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597 · cited 6×
“Localization of spinal cord lesions Cervical, thoracic (29) Thoracic, lumbar (29), involving conus (31)”
BackgroundInfluentialNeuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595 · cited 12×
“Specific antibodies against MOG are detectable in pediatric patients with acute disseminated encephalomyelitis (ADEM) Frontiers in Neurology | www.frontiersin.org 2 October 2018 | Volume 9 | Article 888 TABLE 1 | Epidemiological and clinical features in NMOSD and MOG-EM.”
BackgroundMethodInfluentialSelf-citationRamanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572 · cited 11×
“In patients with myelitis, RTX is recommended from an earlier stage as a myelitis often leads to severe residual deficits (66).”
BackgroundInfluentialAutoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis
Fang, B., McKeon, A., Hinson, S. R., Kryzer, T. J., Pittock, S. J., Aksamit, A. J., & Lennon, V. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2549 · Cited by 568
Flanagan, E. P., Hinson, S. R., Lennon, V. A., Fang, B., Aksamit, A. J., Morris, P. P., Basal, E., Honorat, J. A., Alfugham, N. B., Linnoila, J. J., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24881 · Cited by 550
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study
Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005560 · Cited by 538 · cited 4×
“However, there are indications that MOG-EM has a less severe course than NMOSD and relapse risk depends on Ab status (30, 65, 66).”
BackgroundInfluentialAcute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome
Pohl, D., Alper, G., Van Haren, K., Kornberg, A. J., Lucchinetti, C. F., Tenembaum, S., & Belman, A. L. (2016) · Neurology · doi:10.1212/wnl.0000000000002825 · Cited by 462 · cited 1×
“In the past, MOG-Abs were particularly described in acute disseminated encephalomyelitis (ADEM), an inflammatory CNS disorder that, if it has an pediatric onset, is mostly monophasic and has a favorable outcome in the majority of cases (42, 43).”
BackgroundMyelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
Kitley, J., Woodhall, M., Waters, P., Leite, M. I., Devenney, E., Craig, J., Palace, J., & Vincent, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31826aac4e · Cited by 445 · cited 1×
“Later, MOG-Abs were found in AQP4Ab negative patients with clinical symptoms of NMOSD (91, 92).”
BackgroundMOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., Sato, D. K., Nishiyama, S., Misu, T., Kuroda, H., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000322 · Cited by 436
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul-Enein, F., Waters, P., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 435 · cited 2×
“AQP4Abs usually stay detectable during remission, although the titer may be lower with immunosuppression (some patients even seroconvert to negative over time) and during acute attacks (93).”
BackgroundNeuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses
Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K., Wegner, B., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24554 · Cited by 432 · cited 2×
“In NMOSD, IVMP led to complete recovery in 17–35% of the attacks (15, 173).”
BackgroundSelf-citationin cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0717-1 · Cited by 429 · cited 5×
“The best detection rates are provided by cell-based assays (CBA) (24, 32, 79, 80).”
BackgroundMethodInfluentialSelf-citationHacohen, Y., Wong, Y. Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., Kalser, J., Poulat, A. L., Maurey, H., Ganelin-Cohen, E., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4601 · Cited by 423
Fatigue as a symptom or comorbidity of neurological diseases
Penner, I.-K., & Paul, F. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.117 · Cited by 404
Self-citationPittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395 · cited 1×
“There were encouraging findings from an open label study where 12 out of 14 highly active patients became relapse-free by eculizumab treatment (240, 241).”
ResultMOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390 · cited 16×
“In MOG-EM, approximately 80% of patients with evidence of MOG-Abs during acute attack remained seropositive during remission (33).”
BackgroundResultInfluentialRamanathan, S., Prelog, K., Barnes, E. H., Tantsis, E. M., Reddel, S. W., Henderson, A. P., Vucic, S., Gorman, M. P., Benson, L. A., Alper, G., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515593406 · Cited by 384 · cited 3×
“This can be helpful to diagnose MOG-EM or NMOSD in patients without AQP4-Abs (46, 77, 131, 134, 135).”
BackgroundResultJarius, S., Paul, F., Franciotta, D., Ruprecht, K., Ringelstein, M., Bergamaschi, R., Rommer, P., Kleiter, I., Stich, O., Reuss, R., et al. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.03.038 · Cited by 361 · cited 3×
“AQP4-Abs in CSF can be detected in only 70% of Aqp4-Ab seropositive patients and in none of the AQP4 seronegative patients (100).”
BackgroundSelf-citationReindl, M., Linington, C., Brehm, U., Egg, R., Dilitz, E., Deisenhammer, F., Poewe, W., & Berger, T. (1999) · Brain · doi:10.1093/brain/122.11.2047 · Cited by 347
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Self-citationDemographic and clinical features of neuromyelitis optica: A review
Pandit, L., Asgari, N., Apiwattanakul, M., Palace, J., Paul, F., Leite, M., Kleiter, I., Chitnis, T., & the GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515572406 · Cited by 341 · cited 1×
“Women are disproportionately more often affected and, particularly in AQP4-seropositive patients, female to male-ratio can reach up to 10:1 (19, 22, 23).”
BackgroundSelf-citationBonnan, M., Valentino, R., Debeugny, S., Merle, H., Fergé, J.-L., Mehdaoui, H., & Cabre, P. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316286 · Cited by 337 · cited 1×
“An early initiation of PLEX seems to improve the clinical outcome (176, 177).”
BackgroundMechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica
Jarius, S., Paul, F., Franciotta, D., Waters, P., Zipp, F., Hohlfeld, R., Vincent, A., & Wildemann, B. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0764 · Cited by 335 · cited 2×
“Like in NMOSD, CBA are the current gold standard to detect MOG-Abs (39, 49).”
MethodSelf-citationA 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Kim, S.-H., Huh, S.-Y., Lee, S. J., Joung, A., & Kim, H. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3071 · Cited by 324 · cited 1×
“Thus, currently RTX seems to be the most effective treatment in NMOSD, although some studies describe a rebound in disease activity shortly after RTX induction (199, 206).”
Palace, J., Leite, M. I., Nairne, A., & Vincent, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.188 · Cited by 322
Brilot, F., Dale, R. C., Selter, R. C., Grummel, V., Reddy Kalluri, S., Aslam, M., Busch, V., Zhou, D., Cepok, S., & Hemmer, B. (2009) · Annals of Neurology · doi:10.1002/ana.21916 · Cited by 322
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Jacob, A., Matiello, M., Weinshenker, B. G., Wingerchuk, D. M., Lucchinetti, C., Shuster, E., Carter, J., Keegan, B. M., Kantarci, O. H., & Pittock, S. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.175 · Cited by 308
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Kleiter, I. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.216 · Cited by 294
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
Waters, P., Reindl, M., Saiz, A., Schanda, K., Tuller, F., Kral, V., Nytrova, P., Sobek, O., Nielsen, H. H., Barington, T., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312601 · Cited by 294 · cited 4×
“Like in NMOSD, CBA are the current gold standard to detect MOG-Abs (39, 49).”
BackgroundMethodInfluentialSelf-citationDamato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
Neuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Höftberger, R., Sepulveda, M., Armangue, T., Blanco, Y., Rostásy, K., Cobo Calvo, A., Olascoaga, J., Ramió-Torrentà, L., Reindl, M., Benito-León, J., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514555785 · Cited by 285 · cited 5×
“Like in NMOSD, OCB were detected in 10% of the MOG-EM patients and CSF/serum albumin ratio was elevated in 32% (33, 66, 73).”
BackgroundInfluentialEfficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study
Araki, M., Matsuoka, T., Miyamoto, K., Kusunoki, S., Okamoto, T., Murata, M., Miyake, S., Aranami, T., & Yamamura, T. (2014) · Neurology · doi:10.1212/wnl.0000000000000317 · Cited by 284 · cited 1×
“Tocilizumab, an inhibitor of the IL-6 signaling pathway, showed significant reduction of disease activity in two pilot studies including in total 15 patients with high-active NMOSD (243, 244).”
BackgroundMin, J.-H., Kim, B. J., & Lee, K. H. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511431973 · Cited by 280
The history of neuromyelitis optica
Jarius, S., & Wildemann, B. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-8 · Cited by 279 · cited 1×
“The French term “neuro-myélite optique aiguë,” whichmay be translated as “neuromyelitis optica acuta” was first used byDevic in 1894 (1, 2).”
BackgroundZamvil, S. S., & Slavin, A. J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000062 · Cited by 276 · cited 3×
“Both types of antibodies may lead to disturbances of the integrity of blood brain barrier and to CNS inflammation (53, 60).”
BackgroundThe investigation of acute optic neuritis: a review and proposed protocol
Petzold, A., Wattjes, M. P., Costello, F., Flores-Rivera, J., Fraser, C. L., Fujihara, K., Leavitt, J., Marignier, R., Paul, F., Schippling, S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.108 · Cited by 270
Self-citationJurynczyk, M., Geraldes, R., Probert, F., Woodhall, M. R., Waters, P., Tackley, G., DeLuca, G., Chandratre, S., Leite, M. I., Vincent, A., et al. (2017) · Brain · doi:10.1093/brain/aww350 · Cited by 265
Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
Bennett, J., de Seze, J., Lana-Peixoto, M., Palace, J., Waldman, A., Schippling, S., Tenembaum, S., Banwell, B., Greenberg, B., Levy, M., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514567216 · Cited by 252
Self-citationShort Myelitis Lesions in Aquaporin-4-IgG–Positive Neuromyelitis Optica Spectrum Disorders
Flanagan, E. P., Weinshenker, B. G., Krecke, K. N., Lennon, V. A., Lucchinetti, C. F., McKeon, A., Wingerchuk, D. M., Shuster, E. A., Jiao, Y., Horta, E. S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2137 · Cited by 249 · cited 1×
“do not extend over ≥3 vertebral segments which may lead to misdiagnosis or delayed diagnosis of NMOSD (117).”
BackgroundAzathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica
Costanzi, C., Matiello, M., Lucchinetti, C. F., Weinshenker, B. G., Pittock, S. J., Mandrekar, J., Thapa, P., & McKeon, A. (2011) · Neurology · doi:10.1212/wnl.0b013e31822a2780 · Cited by 249
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Pache, F., Zimmermann, H., Mikolajczak, J., Schumacher, S., Lacheta, A., Oertel, F. C., Bellmann-Strobl, J., Jarius, S., Wildemann, B., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0720-6 · Cited by 246
Self-citationAbboud, H., Petrak, A., Mealy, M., Sasidharan, S., Siddique, L., & Levy, M. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515581438 · Cited by 245 · cited 1×
“In NMOSD, IVMP led to complete recovery in 17–35% of the attacks (15, 173).”
BackgroundUpdated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica
Jiao, Y., Fryer, J. P., Lennon, V. A., Jenkins, S. M., Quek, A. M. L., Smith, C. Y., McKeon, A., Costanzi, C., Iorio, R., Weinshenker, B. G., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cb5c · Cited by 244
Ringelstein, M., Ayzenberg, I., Harmel, J., Lauenstein, A.-S., Lensch, E., Stögbauer, F., Hellwig, K., Ellrichmann, G., Stettner, M., Chan, A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0533 · Cited by 242 · cited 1×
“Tocilizumab, an inhibitor of the IL-6 signaling pathway, showed significant reduction of disease activity in two pilot studies including in total 15 patients with high-active NMOSD (243, 244).”
BackgroundApheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K.-D., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., Kümpfel, T., et al. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000504 · Cited by 240 · cited 2×
“An early initiation of PLEX seems to improve the clinical outcome (176, 177).”
BackgroundSelf-citationRituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD
Das, G., Damotte, V., Gelfand, J. M., Bevan, C. J., Cree, B., Do, L., Green, A., Hauser, S. L., & Bove, R. M. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000453 · Cited by 232
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
Hacohen, Y., Absoud, M., Deiva, K., Hemingway, C., Nytrova, P., Woodhall, M., Palace, J., Wassmer, E., Tardieu, M., Vincent, A., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000081 · Cited by 230
Hamid, S. H. M., Whittam, D., Mutch, K., Linaker, S., Solomon, T., Das, K., Bhojak, M., & Jacob, A. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8596-7 · Cited by 222
Hamid, S. H. M., Whittam, D., Saviour, M., Alorainy, A., Mutch, K., Linaker, S., Solomon, T., Bhojak, M., Woodhall, M., Waters, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3196 · Cited by 214 · cited 1×
“Hence, there is the risk miss a typical MRI presentation of the LETM when the MRI is performed too early or too late (72).”
BackgroundNeuromyelitis optica in France: A multicenter study of 125 patients
Collongues, N., Marignier, R., Zéphir, H., Papeix, C., Blanc, F., Ritleng, C., Tchikviladzé, M., Outteryck, O., Vukusic, S., Fleury, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d31e35 · Cited by 213
Kim, S.-H., Jeong, I. H., Hyun, J.-W., Joung, A., Jo, H.-J., Hwang, S.-H., Yun, S., Joo, J., & Kim, H. J. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1276 · Cited by 211
The current role of MRI in differentiating multiple sclerosis from its imaging mimics
on behalf of the MAGNIMS study group, Geraldes, R., Ciccarelli, O., Barkhof, F., De Stefano, N., Enzinger, C., Filippi, M., Hofer, M., Paul, F., Preziosa, P., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.14 · Cited by 210 · cited 1×
“It helps to differentiate NMOSD from MS and other CNS disorders (115).”
BackgroundSelf-citationJarius, S., Franciotta, D., Paul, F., Ruprecht, K., Bergamaschi, R., Rommer, P. S., Reuss, R., Probst, C., Kristoferitsch, W., Wandinger, K. P., et al. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-52 · Cited by 209 · cited 1×
“Testing CSF for AQP4- or MOG Abs is not routinely recommended as it does not seem to provide an additional benefit for diagnosing NMOSD orMOG-EM (98, 99).”
BackgroundSelf-citationAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica
Papeix, C., Vidal, J.-S., Seze, J. D., Pierrot-Deseilligny, C., Tourbah, A., Stankoff, B., Lebrun, C., Moreau, T., Vermersch, P., Fontaine, B., et al. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506070732 · Cited by 204
Zekeridou, A., & Lennon, V. A. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000110 · Cited by 203
dos Passos, G. R., Oliveira, L. M., da Costa, B. K., Apostolos-Pereira, S. L., Callegaro, D., Fujihara, K., & Sato, D. K. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00217 · Cited by 200 · cited 2×
“Although there are numerous overlaps in clinical presentation and imaging findings with NMOSD with and without AQP4-Ab, MOG-Ab-associated disease is more and more considered a disease entity in its own (47).”
BackgroundXiao, B.-G., Linington, C., & Link, H. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90014-x · Cited by 197 · cited 1×
“In MS patients, MOG-Abs were described for the first time at the beginning of the 1990s (87).”
BackgroundBrainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients
Kremer, L., Mealy, M., Jacob, A., Nakashima, I., Cabre, P., Bigi, S., Paul, F., Jarius, S., Aktas, O., Elsone, L., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513507822 · Cited by 196 · cited 1×
“, area postrema syndrome or diencephalic syndrome can occur (8, 9).”
BackgroundSelf-citationNikoo, Z., Badihian, S., Shaygannejad, V., Asgari, N., & Ashtari, F. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8590-0 · Cited by 192 · cited 3×
“54% of the patient treated with AZA became relapse free after 1 year (178).”
BackgroundResultEffects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
Takeshita, Y., Obermeier, B., Cotleur, A. C., Spampinato, S. F., Shimizu, F., Yamamoto, E., Sano, Y., Kryzer, T. J., Lennon, V. A., Kanda, T., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000311 · Cited by 188 · cited 1×
“Both types of antibodies may lead to disturbances of the integrity of blood brain barrier and to CNS inflammation (53, 60).”
BackgroundDiscriminating long myelitis of neuromyelitis optica from sarcoidosis
Flanagan, E. P., Kaufmann, T. J., Krecke, K. N., Aksamit, A. J., Pittock, S. J., Keegan, B. M., Giannini, C., & Weinshenker, B. G. (2016) · Annals of Neurology · doi:10.1002/ana.24582 · Cited by 188 · cited 2×
“To exclude sarcoidosis which is a relevant differential diagnosis as it can also manifest with optic neuropathy or myelopathy (112, 113), tests on hypercalcemia and hypercalciuria, interleukin-2-rezeptor (sIL-2 R), and angiotensin-converting enzyme (ACE) should be performed (112, 114).”
BackgroundMOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder
Narayan, R., Simpson, A., Fritsche, K., Salama, S., Pardo, S., Mealy, M., Paul, F., & Levy, M. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.07.025 · Cited by 187
Self-citationSchneider, E., Zimmermann, H., Oberwahrenbrock, T., Kaufhold, F., Kadas, E. M., Petzold, A., Bilger, F., Borisow, N., Jarius, S., Wildemann, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066151 · Cited by 183
Self-citationB lymphocytes in neuromyelitis optica
Bennett, J. L., O'Connor, K. C., Bar-Or, A., Zamvil, S. S., Hemmer, B., Tedder, T. F., von Büdingen, H.-C., Stuve, O., Yeaman, M. R., Smith, T. J., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000104 · Cited by 182 · cited 1×
“RTX leads to a depletion of CD20+Blymphocytes, which act as precursor cells of antibody producing plasma cells (187).”
BackgroundHistopathology and clinical course of MOG-antibody-associated encephalomyelitis
Spadaro, M., Gerdes, L. A., Mayer, M. C., Ertl-Wagner, B., Laurent, S., Krumbholz, M., Breithaupt, C., Högen, T., Straube, A., Giese, A., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.164 · Cited by 176 · cited 11×
“Specific antibodies against MOG are detectable in pediatric patients with acute disseminated encephalomyelitis (ADEM) Frontiers in Neurology | www.frontiersin.org 2 October 2018 | Volume 9 | Article 888 TABLE 1 | Epidemiological and clinical features in NMOSD and MOG-EM.”
ResultInfluentialAntibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton
Dale, R. C., Tantsis, E. M., Merheb, V., Kumaran, R.-Y. A., Sinmaz, N., Pathmanandavel, K., Ramanathan, S., Booth, D. R., Wienholt, L. A., Prelog, K., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000012 · Cited by 173 · cited 14×
“In MOG-EM, approximately 80% of patients with evidence of MOG-Abs during acute attack remained seropositive during remission (33).”
BackgroundInfluentialLow-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis
Watanabe, S., Misu, T., Miyazawa, I., Nakashima, I., Shiga, Y., Fujihara, K., & Itoyama, Y. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507077189 · Cited by 172 · cited 1×
“A few studies could show a decrease in ARR by low dose steroid therapy (181, 182).”
BackgroundFrequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis
Jarius, S., Frederikson, J., Waters, P., Paul, F., Akman-Demir, G., Marignier, R., Franciotta, D., Ruprecht, K., Kuenz, B., Rommer, P., et al. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.07.011 · Cited by 170
Self-citationBrain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
Juryńczyk, M., Tackley, G., Kong, Y., Geraldes, R., Matthews, L., Woodhall, M. R., Waters, P. J., Küker, W., Craner, M. J., Weir, A., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314005 · Cited by 165
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
Stellmann, J., Krumbholz, M., Friede, T., Gahlen, A., Borisow, N., Fischer, K., Hellwig, K., Pache, F. C., Ruprecht, K., Havla, J. B., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315603 · Cited by 164 · cited 1×
“A few studies could show a decrease in ARR by low dose steroid therapy (181, 182).”
BackgroundSelf-citationJarius, S., Jacobi, C., de Seze, J., Zephir, H., Paul, F., Franciotta, D., Rommer, P., Mader, S., Kleiter, I., Reindl, M., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511403958 · Cited by 162
Self-citationLongitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases
Hyun, J., Woodhall, M. R., Kim, S., Jeong, I. H., Kong, B. S., Kim, G., Kim, Y., Park, M. S., Irani, S. R., Waters, P. J., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315998 · Cited by 160 · cited 2×
“However, the rate was lower with only 50% of patients remaining seropositive in a study from Korea (76).”
BackgroundTreatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica
Merle, H., Olindo, S., Jeannin, S., Valentino, R., Mehdaoui, H., Cabot, F., Donnio, A., Hage, R., Richer, R., Smadja, D., et al. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.1126 · Cited by 156
Iyer, A., Elsone, L., Appleton, R. E., & Jacob, A. (2014) · Autoimmunity · doi:10.3109/08916934.2014.883501 · Cited by 155
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
Sepúlveda, M., Armangué, T., Sola-Valls, N., Arrambide, G., Meca-Lallana, J. E., Oreja-Guevara, C., Mendibe, M., Alvarez de Arcaya, A., Aladro, Y., Casanova, B., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000225 · Cited by 154
Evaluation of aquaporin‐4 antibody assays
Waters, P. J., Pittock, S. J., Bennett, J. L., Jarius, S., Weinshenker, B. G., & Wingerchuk, D. M. (2014) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12107 · Cited by 154 · cited 2×
“Like in NMOSD, CBA are the current gold standard to detect MOG-Abs (39, 49).”
MethodElsone, L., Panicker, J., Mutch, K., Boggild, M., Appleton, R. E., & Jacob, A. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513495938 · Cited by 153 · cited 1×
“One study investigated IVIG treatment of acute NMOSD relapses (214), however, further data on preventive IVIG therapy is lacking.”
BackgroundClinical utility of testing AQP4-IgG in CSF
Majed, M., Fryer, J. P., McKeon, A. B., Lennon, V. A., & Pittock, S. J. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000231 · Cited by 149 · cited 1×
“Testing CSF for AQP4- or MOG Abs is not routinely recommended as it does not seem to provide an additional benefit for diagnosing NMOSD orMOG-EM (98, 99).”
BackgroundInsufficient treatment of severe depression in neuromyelitis optica spectrum disorder
Chavarro, V. S., Mealy, M. A., Simpson, A. C., Lacheta, A., Pache, F. C., Ruprecht, K., Gold, S. M., Paul, F., Brandt, A. U., & Levy, M. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000286 · Cited by 146
Self-citationNakamura, M., Nakazawa, T., Doi, H., Hariya, T., Omodaka, K., Misu, T., Takahashi, T., Fujihara, K., & Nishida, K. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1344-7 · Cited by 145
Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
Oertel, F. C., Kuchling, J., Zimmermann, H. G., Chien, C., Schmidt, F., Knier, B., Bellmann–Strobl, J., Korn, T., Scheel, M., Klistorner, A. I., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000334 · Cited by 144
Self-citationPekcevik, Y., Mitchell, C. H., Mealy, M. A., Orman, G., Lee, I. H., Newsome, S. D., Thompson, C. B., Pardo, C. A., Calabresi, P. A., Levy, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515591069 · Cited by 141 · cited 1×
“Typical NMOSD lesions are located centrally in the spinal cord and involve more than the half of spinal cord cross-section area (118).”
BackgroundAkaishi, T., Sato, D. K., Nakashima, I., Takeshita, T., Takahashi, T., Doi, H., Kurosawa, K., Kaneko, K., Kuroda, H., Nishiyama, S., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310206 · Cited by 141 · cited 13×
“This can be helpful to diagnose MOG-EM or NMOSD in patients without AQP4-Abs (46, 77, 131, 134, 135).”
BackgroundInfluentialJarius, S., Paul, F., Franciotta, D. M., Seze, J. D., Münch, C., Salvetti, M., Ruprecht, K., Liebetrau, M., Wandinger, K. P., Akman‐Demir, G., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511431728 · Cited by 140
Self-citationMOG antibody-related disorders: common features and uncommon presentations
Cobo‐Calvo, Á., Ruiz, A., d’Indy, H., Poulat, A., Carneiro, M., Nicolas, P., Durand‐Dubief, F., Deiva, K., Vukusic, S., Portes, V. D., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8583-z · Cited by 137 · cited 1×
“In patients with MOGAbs, optic neuritis was the first clinical manifestation in 33– 64% whereas myelitis occurred in 18–33% of the patients as initial symptom (33, 48, 65).”
BackgroundDuignan, S. M., Wright, S. K., Rossor, T., Cazabon, J., Gilmour, K. C., Ciccarelli, O., Wassmer, E., Lim, M. J., Hemingway, C. A., & Hacohen, Y. (2018) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.13703 · Cited by 136
Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies
Fujimori, J., Takai, Y., Nakashima, I., Sato, D. K., Takahashi, T., Kaneko, K., Nishiyama, S., Watanabe, M., Tanji, H., Kobayashi, M., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315094 · Cited by 135
Yonezu, T., Ito, S., Mori, M., Ogawa, Y., Makino, T., Uzawa, A., & Kuwabara, S. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513495581 · Cited by 130 · cited 1×
“It was suggested by Yonezu et al.(119) that “bright spotty lesions” are characteristic for NMOSD and might reflect microcystic defects of the spinal cord (113).”
BackgroundSelf-citationElsone, L., Kitley, J., Luppe, S., Lythgoe, D. T., Mutch, K., Jacob, S., Brown, R. L., Moss, K., McNeillis, B., Goh, Y. Y., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514525870 · Cited by 128
Update on biomarkers in neuromyelitis optica
Melamed, E., Levy, M., Waters, P. J., Sato, D. K., Bennett, J. L., John, G. R., Hooper, D. C., Saiz, A., Bar‐Or, A., Kim, H. J., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000134 · Cited by 128 · cited 1×
“In 20–30% of patients, depending on the assay used, AQP4-Abs are not detectable (24, 25).”
BackgroundSelf-citationRetinal ganglion cell loss in neuromyelitis optica: a longitudinal study
Oertel, F. C., Havla, J. B., Roca‐Fernández, A., Lizak, N., Zimmermann, H. G., Motamedi, S., Borisow, N., White, O. B., Bellmann–Strobl, J., Albrecht, P., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318382 · Cited by 124
Self-citationMicrocystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica
Gelfand, J. M., Cree, B. A., Nolan, R., Arnow, S., & Green, A. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1832 · Cited by 123
Optic neuropathy associated with systemic sarcoidosis
Kidd, D. P., Burton, B., GRAHAM, E. M., & Plant, G. T. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000270 · Cited by 122 · cited 2×
“To exclude sarcoidosis which is a relevant differential diagnosis as it can also manifest with optic neuropathy or myelopathy (112, 113), tests on hypercalcemia and hypercalciuria, interleukin-2-rezeptor (sIL-2 R), and angiotensin-converting enzyme (ACE) should be performed (112, 114).”
BackgroundMontcuquet, A., Collongues, N., Papeix, C., Zéphir, H., Audoin, B., Laplaud, D. A., Bourre, B., Brochet, B., Camdessanché, J., Labauge, P. M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516678474 · Cited by 121 · cited 2×
“The administered daily dose ranges between 750 and 3,000 mg/d (179, 208, 209).”
BackgroundNeuromyelitis optica: Effect of gender
Wingerchuk, D. M. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.045 · Cited by 121 · cited 1×
“Women are disproportionately more often affected and, particularly in AQP4-seropositive patients, female to male-ratio can reach up to 10:1 (19, 22, 23).”
BackgroundPresent and Future Therapies in Neuromyelitis Optica Spectrum Disorders
Kleiter, I., & Gold, R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0400-8 · Cited by 120 · cited 1×
“The most frequently used dose regimen is the intravenous administration of each 1,000mg with an interval of 2 weeks followed by 6-monthly dosages of 1,000mg (179, 188).”
MethodOligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function
Vourc’h, P., & Andres, C. R. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.01.003 · Cited by 118 · cited 1×
“MOG is a glycoprotein localized on the surface of the myelin sheath as well as of the cell body and processes of oligodendrocytes (44, 45).”
BackgroundSchmidt, F., Zimmermann, H. G., Mikolajczak, J., Oertel, F. C., Pache, F. C., Weinhold, M., Schinzel, J., Bellmann–Strobl, J., Ruprecht, K., Paul, F., et al. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.11.008 · Cited by 118
Self-citationJarius, S., Metz, I., König, F. B., Ruprecht, K., Reindl, M., Paul, F., Brück, W., & Wildemann, B. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515622986 · Cited by 116 · cited 11×
“Specific antibodies against MOG are detectable in pediatric patients with acute disseminated encephalomyelitis (ADEM) Frontiers in Neurology | www.frontiersin.org 2 October 2018 | Volume 9 | Article 888 TABLE 1 | Epidemiological and clinical features in NMOSD and MOG-EM.”
ResultInfluentialSelf-citationChen, D., Gallagher, S., Monson, N. L., Herbst, R., & Wang, Y. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5120107 · Cited by 116
van Pelt, E. D., Wong, Y. Y. M., Ketelslegers, I. A., Hamann, D., & Hintzen, R. Q. (2016) · European Journal of Neurology · doi:10.1111/ene.12898 · Cited by 110 · cited 2×
“In AQP4-Ab positive NMOSD, most patients (80– 90%) have a relapsing disease course (26, 73, 74).”
BackgroundResultSepúlveda, M., Aldea, M., Escudero, D., Llufriú, S., Arrambide, G., Otero‐Romero, S., Sastre‐Garriga, J., Romero-Pinel, L., Martínez‐Yélamos, S., Solà‐Valls, N., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517735191 · Cited by 109 · cited 1×
“Using the 2015 instead of the 2006 criteria led to a significant increase in the number of patients diagnosed with NMOSD (138, 171, 172) For MOG-EM, to date, no evidence based diagnostic criteria exist.”
MethodNeuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss
Ratelade, J., Zhang, H., Saadoun, S., Bennett, J. L., Papadopoulos, M. C., & Verkman, A. S. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0986-4 · Cited by 108 · cited 1×
“However, while inflammation in MOG-EM primarily results in demyelination, demyelination in NMOSD seems to be a secondary phenomenon following astrocytic damage (61, 62).”
BackgroundWorldwide prevalence of neuromyelitis optica spectrum disorders
Mori, M., Kuwabara, S., & Paul, F. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317566 · Cited by 108
Self-citationSpecific pattern of gadolinium enhancement in spondylotic myelopathy
Flanagan, E. P., Krecke, K. N., Marsh, R. W., Giannini, C., Keegan, B. M., & Weinshenker, B. G. (2014) · Annals of Neurology · doi:10.1002/ana.24184 · Cited by 108 · cited 1×
“Other causes for longitudinally extensive spinal cord LETM lesions include sarcoidosis or spondylotic myelopathy or rarely MS and need to be considered (112, 122, 123).”
BackgroundKitley, J., Elsone, L., George, J., Waters, P. J., Woodhall, M. R., Vincent, A. C., Jacob, A., Leite, M. I., & Palace, J. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304774 · Cited by 101 · cited 1×
“Therefore, MTX seems to be a treatment option in patients that do not respond to first-linetherapy or suffer from side effects of other treatments (216).”
BackgroundRituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
Zéphir, H., Bernard‐Valnet, R., Lebrun‐Frénay, C., Outteryck, O., Audoin, B., Bourre, B., Pittion, S., Wiertlewski, S., Ouallet, J., Neau, J., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7852-y · Cited by 99
Asgari, N., Skejoe, H. P. B., Lillevang, S. T., Steenstrup, T., Stenager, E., & Kyvik, K. O. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-33 · Cited by 99 · cited 1×
“They may not be present from relapse onset and may change into multiple short lesions or into spinal cord atrophy during the disease course (120, 121).”
BackgroundHavla, J. B., Kümpfel, T., Schinner, R., Spadaro, M., Schuh, E., Meinl, E., Hohlfeld, R., & Outteryck, O. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8333-7 · Cited by 98
Oertel, F. C., Zimmermann, H. G., Paul, F., & Brandt, A. U. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0123-5 · Cited by 98
Self-citationA population-based prospective study of optic neuritis
Soelberg, K. K., Jarius, S., Skejoe, H., Engberg, H., Mehlsen, J., Nilsson, A. C., Madsen, J. S., Reindl, M., Wildemann, B., Grauslund, J., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517734070 · Cited by 98
Self-citationEfficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica
Kim, S.-H., Kim, W., Park, M. S., Sohn, E. H., Li, X. F., & Kim, H. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.322 · Cited by 98 · cited 1×
“Mitoxantrone is able to significantly reduce ARR in NMOSD patients (231, 232), nevertheless, due to its cardio- and myelotoxic side effects and the availability of alternatives with fewer adverse events its use should be considered very critically (233–235).”
BackgroundNarcolepsy as an initial manifestation of neuromyelitis optica with antiaquaporin-4 antibody
Baba, T., Nakashima, I., Kanbayashi, T., Konno, M., Takahashi, T., Fujihara, K., Misu, T., Takeda, A., Shiga, Y., Ogawa, H., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0139-4 · Cited by 96
Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
Asseyer, S., Schmidt, F., Chien, C., Scheel, M., Ruprecht, K., Bellmann–Strobl, J., Brandt, A. U., & Paul, F. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217318796684 · Cited by 94
Self-citationInfluence of female sex and fertile age on neuromyelitis optica spectrum disorders
Borisow, N., Kleiter, I., Gahlen, A., Fischer, K., Wernecke, K., Pache, F. C., Ruprecht, K., Havla, J. B., Krumbholz, M., Kümpfel, T., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516671203 · Cited by 93 · cited 1×
“Women are disproportionately more often affected and, particularly in AQP4-seropositive patients, female to male-ratio can reach up to 10:1 (19, 22, 23).”
BackgroundSelf-citationMortality in neuromyelitis optica is strongly associated with African ancestry
Mealy, M. A., Kessler, R. A., Rimler, Z., Reid, A., Totonis, L., Cutter, G., Kister, I., & Levy, M. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000468 · Cited by 92 · cited 1×
“Patients without long-term immunosuppressive therapy have a worse prognosis with a higher mortality rate (17).”
BackgroundRituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
Marcinnò, A., Marnetto, F., Valentino, P., Martire, S., Balbo, A., Drago, A., Leto, M., Capobianco, M. A. N., Panzica, G., & Bertolotto, A. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000498 · Cited by 91 · cited 1×
“Moreover, neurologists must be aware of hypogammaglobulinemia that may occur with long-term RTX treatment (194).”
BackgroundEvaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder
Hyun, J., Jeong, I. H., Joung, A., Kim, S., & Kim, H. J. (2016) · Neurology · doi:10.1212/wnl.0000000000002655 · Cited by 89 · cited 1×
“Using the 2015 instead of the 2006 criteria led to a significant increase in the number of patients diagnosed with NMOSD (138, 171, 172) For MOG-EM, to date, no evidence based diagnostic criteria exist.”
MethodRituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
Nosadini, M., Alper, G. P., Riney, C. J., Benson, L. A., Mohammad, S. S., Ramanathan, S., Nolan, M. A., Appleton, R. E., Leventer, R. J., Deiva, K., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000188 · Cited by 89
Analysis of the treatment of neuromyelitis optica
Torres, J., Pruitt, A. A., Balcer, L. J., Galetta, S. L., Markowitz, C., & Dahodwala, N. A. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.02.012 · Cited by 88
Sleep abnormality in neuromyelitis optica spectrum disorder
Song, Y., Pan, L., Fu, Y., Sun, N., Li, Y.-J., Cai, H., Su, L., Shen, Y., Cui, L., & Shi, F. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000094 · Cited by 88
Multicenter reliability of semiautomatic retinal layer segmentation using OCT
Oberwahrenbrock, T., Traber, G. L., Lukas, S., Gabilondo, I., Nolan, R., Songster, C., Balk, L., Petzold, A., Paul, F., Villoslada, P., et al. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000449 · Cited by 86
Self-citationLalive, P. H., Häusler, M., Maurey, H., Mikaeloff, Y., Tardieu, M., Wiendl, H., Schroeter, M., Hp, H., Kieseier, B., & Menge, T. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510389220 · Cited by 86
Monitoring B-cell repopulation after depletion therapy in neurologic patients
Ellwardt, E., Ellwardt, L., Bittner, S., & Zipp, F. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000463 · Cited by 85 · cited 1×
“As an alternative to a fixed dosage regimen every 6 months, monitoring of CD19+/CD20+ B-lymphocytes and administration of RTX in the case of reconstitution of these cells is possible (189, 190).”
BackgroundRadaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V, Ferrè, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V, et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515594042 · Cited by 85
Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica
Akaishi, T., Nakashima, I., Takeshita, T., Mugikura, S., Sato, D. K., Takahashi, T., Nishiyama, S., Kurosawa, K., Misu, T., Nakazawa, T., et al. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.02.004 · Cited by 84 · cited 11×
“This can be helpful to diagnose MOG-EM or NMOSD in patients without AQP4-Abs (46, 77, 131, 134, 135).”
BackgroundInfluentialFrequencies of neuronal autoantibodies in healthy controls: Estimation of disease specificity
Lang, K., & Prüß, H. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000386 · Cited by 82
Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
Cree, B., Bennett, J. L., Sheehan, M., Cohen, J. A., Hartung, H.-P., Aktaş, O., Kim, H. J., Paul, F., Pittock, S. J., Weinshenker, B. G., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515620934 · Cited by 81
Self-citationChen, H., Qiu, W., Zhang, Q., Wang, J., Shi, Z., Liu, J., Lian, Z., Feng, H., Miao, X., & Zhou, H. (2016) · European Journal of Neurology · doi:10.1111/ene.13186 · Cited by 79 · cited 1×
“Other observational studies showed similar results with proportions of relapse-free patients between 56 and 60% in NMOSD (210, 211) In comparison to AZA,MMF showed fewer side effects with equal efficacy (211, 212).”
ResultYang, Y., Wang, C.-J., Wang, B., Zeng, Z., & Guo, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.12.034 · Cited by 79 · cited 1×
“Other observational studies showed similar results with proportions of relapse-free patients between 56 and 60% in NMOSD (210, 211) In comparison to AZA,MMF showed fewer side effects with equal efficacy (211, 212).”
ResultBrain magnetic resonance imaging findings in relapsing neuromyelitis optica
Cabrera-Gómez, J. A., Quevedo-Sotolongo, L., González-Quevedo, A., Lima, S., Real-González, Y., Cristófol-Corominas, M., Romero-García, K., Ugarte-Sánchez, C., Jordán-González, J., Nuez, J. G. D. L., et al. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506070725 · Cited by 77
Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder
Jeong, I. H., Kim, H. J., Kim, N., Jeong, K. S., & Park, C. Y. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8138-8 · Cited by 74
Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study
Valentino, P., Marnetto, F., Granieri, L., Capobianco, M. A. N., & Bertolotto, A. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000317 · Cited by 72 · cited 1×
“In some studies, Ab-titers were associated with relapses and treatment status (32, 93, 94).”
BackgroundDisruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
Asgari, N., Flanagan, E. P., Fujihara, K., Kim, H. J., Skejø, H. P. B., Wuerfel, J. T., Kuroda, H., Kim, S. H., Maillart, É., Marignier, R., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000343 · Cited by 71 · cited 1×
“Meningeal enhancement has been reported in some cases, although this does not appear to be a very frequent imaging finding in NMOSD (133).”
BackgroundSelf-citationMOG antibody-associated diseases
Reindl, M., & Rostasy, K. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000060 · Cited by 70 · cited 1×
“To date, the relevance of MOG-Abs and their nosologic categorization is a topic of current discussion and under further investigation (47, 52, 53).”
BackgroundThe impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates
Hamid, S. H. M., Elsone, L., Mutch, K., Solomon, T., & Jacob, A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516663853 · Cited by 70 · cited 1×
“Using the 2015 instead of the 2006 criteria led to a significant increase in the number of patients diagnosed with NMOSD (138, 171, 172) For MOG-EM, to date, no evidence based diagnostic criteria exist.”
MethodDisease exacerbation after rituximab induction in neuromyelitis optica
Perumal, J. S., Kister, I., Howard, J., & Herbert, J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000061 · Cited by 69
Neuromyelitis Optica Study Group (NEMOS), Ayzenberg, I., Schöllhammer, J., Hoepner, R., Hellwig, K., Ringelstein, M., Aktaş, O., Kümpfel, T., Krumbholz, M., Trebst, C., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-015-7991-1 · Cited by 68
Self-citationNormal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
Finke, C., Heine, J., Pache, F. C., Lacheta, A., Borisow, N., Kuchling, J., Bellmann–Strobl, J., Ruprecht, K., Brandt, A. U., & Paul, F. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000229 · Cited by 68
Self-citationPittock, S. J., Lennon, V. A., Bakshi, N., Shen, L., McKeon, A., Quach, H., Briggs, F. B. S., Bernstein, A. L., Schaefer, C. A., & Barcellos, L. F. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1581 · Cited by 67
Stiebel-Kalish, H., Lotan, I., Brody, J., Chodick, G., Bialer, O., Marignier, R., Bach, M., & Hellmann, M. A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170847 · Cited by 67
Diagnosis and therapy of acute disseminated encephalomyelitis and its variants
Berzero, G., Cortese, A., Ravaglia, S., & Marchioni, E. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1126510 · Cited by 67 · cited 1×
“In the past, MOG-Abs were particularly described in acute disseminated encephalomyelitis (ADEM), an inflammatory CNS disorder that, if it has an pediatric onset, is mostly monophasic and has a favorable outcome in the majority of cases (42, 43).”
BackgroundAboul‐Enein, F., Seifert‐Held, T., Mader, S., Kuenz, B., Lutterotti, A., Rauschka, H., Rommer, P. S., Leutmezer, F., Vass, K., Flamm-Horak, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079649 · Cited by 67 · cited 1×
“In patients with AQP4-Abs, the most frequent symptoms at onset are optic neuritis in 37-54% of the patients, and LETM in 30–47% of the patients (26, 63, 64).”
BackgroundMOG antibodies in combined central and peripheral demyelination syndromes
Campo, R. V. D., Stephens, A., Collazo, I. V. M., & Rubin, D. I. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000503 · Cited by 67 · cited 1×
“Rarer clinical manifestations of NMOSD comprise narcolepsy, acute diencephalic syndrome or muscle affection (54, 55), while in MOG-EM extraneural involvement such as reversible paraspinal muscle hyperintensity have been described, as well as MOG-Abs in combined central and peripheral demyelination syndromes (56, 57).”
BackgroundJarius, S., Ruprecht, K., Stellmann, J., Huss, A. M., Ayzenberg, I., Willing, A., Trebst, C., Pawlitzki, M., Abdelhak, A., Grüter, T., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1108-6 · Cited by 67 · cited 1×
“Testing of patients with progressive MS for MOG antibodies is not warranted under most circumstances (97).”
BackgroundSelf-citationRecommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
Ciron, J., Audoin, B., Bourre, B., Brassat, D., Durand‐Dubief, F., Laplaud, D. A., Maillart, É., Papeix, C., Vukusic, S., Zéphir, H., et al. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2017.11.005 · Cited by 66 · cited 2×
“An update of vaccination status and anti-pneumococcal vaccination is recommended (192).”
BackgroundUse of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder
Kremer, S., Renard, F., Achard, S., Lana–Peixoto, M. A., Palace, J. A., Asgari, N., Klawiter, E. C., Tenembaum, S. N., Banwell, B., Greenberg, B. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0248 · Cited by 66
Self-citationCohen, M., Romero, G., Bas, J., Ticchioni, M., Rosenthal, M., Lacroix, R., Brunet, C., Rico, A., Pelletier, J., Audoin, B., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.01.025 · Cited by 66 · cited 1×
“Another option is the administration of RTX depending on monitoring of CD27+ memory B-cells which might in some cases allow to lower the cumulative RTX dose (191).”
BackgroundEfficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study
Cabre, P., Olindo, S., Marignier, R., Jeannin, S., Merle, H., Smadja, D., & Sclerosis, U. T. A. O. T. F. N. O. O. M. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303121 · Cited by 65 · cited 1×
“Mitoxantrone is able to significantly reduce ARR in NMOSD patients (231, 232), nevertheless, due to its cardio- and myelotoxic side effects and the availability of alternatives with fewer adverse events its use should be considered very critically (233–235).”
BackgroundWildemann, B., Jarius, S., & Paul, F. (2013) · Der Nervenarzt · doi:10.1007/s00115-012-3602-x · Cited by 64
Self-citationVery late-onset neuromyelitis optica spectrum disorder beyond the age of 75
Krumbholz, M., Oy, U. H., Angstwurm, K., Kleiter, I., Jarius, S., Paul, F., Aktaş, O., Buchholz, G., Kern, P., Straube, A. M., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7766-8 · Cited by 63
Self-citationMealy, M. A., Kim, S., Schmidt, F., López-González, R., Arango, J. A. J., Paul, F., Wingerchuk, D. M., Greenberg, B. M., Kim, H. J., & Levy, M. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517730131 · Cited by 63 · cited 3×
“Treatment effect does not seem to depend on AQP4-serostatus (96).”
BackgroundSelf-citationMassive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
Gelfand, J. M., Cotter, J. A., Klingman, J. G., Huang, E. J., & Cree, B. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000034 · Cited by 61
Brain parenchymal damage in neuromyelitis optica spectrum disorder – A multimodal MRI study
Pache, F. C., Zimmermann, H. G., Finke, C., Lacheta, A., Papazoglou, S., Kuchling, J., Wuerfel, J. T., Hamm, B., Ruprecht, K., Paul, F., et al. (2016) · European Radiology · doi:10.1007/s00330-016-4282-x · Cited by 60
Self-citationAungsumart, S., & Apiwattanakul, M. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.02.015 · Cited by 58
Restoring immune tolerance in neuromyelitis optica: Part II
Bar‐Or, A., Steinman, L., Behne, J. M., Benítez‐Ribas, D., Chin, P. S., Clare-Salzler, M. J., Healey, D. G., Kim, J. I., Kranz, D. M., Lutterotti, A., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000277 · Cited by 57
Self-citationSerum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
Metz, I., Beißbarth, T., Ellenberger, D., Pache, F. C., Stork, L., Ringelstein, M., Aktaş, O., Jarius, S., Wildemann, B., Dihazi, H., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000204 · Cited by 56
Self-citationAlemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series
Azzopardi, L., Cox, A. L., McCarthy, C., Jones, J., & Coles, A. J. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7925-y · Cited by 56
Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study
On behalf of Francophone Society of Multiple Sclerosis and OFSEP investigators, Cabre, P., Mejdoubi, M., Jeannin, S., Merle, H., Plumelle, Y., Cavillon, G., Smadja, D., & Marignier, R. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8771-5 · Cited by 54
Zhang, M., Zhang, C., Bai, P., Xue, H., & Wang, G. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0795-6 · Cited by 54 · cited 1×
“With regards to ARR and EDSS, comparison studies between both drugs seem to suggest a superiority of RTX compared to AZA (178, 184).”
ResultFinke, C., Zimmermann, H. G., Pache, F. C., Oertel, F. C., Chavarro, V. S., Kramarenko, Y., Bellmann–Strobl, J., Ruprecht, K., Brandt, A. U., & Paul, F. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3890 · Cited by 54
Self-citationAquaporin-4 antibodies in patients treated with natalizumab for suspected MS
Gahlen, A., Trampe, A.-K., Haupeltshofer, S., Ringelstein, M., Aktaş, O., Berthele, A., Wildemann, B., Gold, R., Jarius, S., & Kleiter, I. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000363 · Cited by 53
Optical coherence tomography in acute optic neuritis: A population-based study
Soelberg, K. K., Specovius, S., Zimmermann, H. G., Grauslund, J., Mehlsen, J., Olesen, C., Neve, A. S. B., Paul, F., Brandt, A. U., & Asgari, N. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.13004 · Cited by 51
Self-citationIntravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica
Viswanathan, S., Wong, H. Y., Quek, A. M. L., & Yuki, N. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.03.021 · Cited by 51
Haase, C. G., & Schmidt, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01949-8 · Cited by 50
Yamout, B., Beaini, S., Zeineddine, M. M., & Akkawi, N. M. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517694086 · Cited by 50
Lack of Response to Pulse Cyclophosphamide in Neuromyelitis Optica: Evaluation of 7 Patients
Bichuetti, D. B., Oliveira, E. M. L., Boulos, F. D. C., & Gabbai, A. A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.545 · Cited by 50 · cited 1×
“Cyclophosphamide does not seem to be effective in NMOSD (236).”
BackgroundAssociation of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis
Uzawa, A., Mori, M., Iwai, Y., Kobayashi, M., Hayakawa, S., Kawaguchi, N., & Kuwabara, S. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.040 · Cited by 48
Self-citationOptical coherence tomography and visual evoked potentials in pediatric MS
Waldman, A. T., Liu, G. T., Lavery, A. M., Liu, G., Gaetz, W. C., Alemán, T. S., & Banwell, B. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000356 · Cited by 48
Investigational drugs in development to prevent neuromyelitis optica relapses
Paul, F., Murphy, O., Pardo, S., & Levy, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1443077 · Cited by 46
Self-citationManagement issues with exogenous steroid therapy
Bandgar, T., Patt, H., Lila, A. R., & Shah, N. S. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.123548 · Cited by 46 · cited 1×
“peptic ulcer, psychiatric disturbances and a Cushing syndrome (180).”
BackgroundGRAID investigators, Rommer, P. S., Dörner, T., Freivogel, K., Haas, J., Kieseier, B. C., Kümpfel, T., Paul, F., Proft, F. N., Schulze‐Koops, H., et al. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9646-5 · Cited by 45 · cited 1×
“, arrhythmia or cardiac insufficiency were reported (193).”
BackgroundSelf-citationBeauchemin, P., Iorio, R., Traboulsee, A. L., Field, T. S., Tinker, A. V., & Carruthers, R. L. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.12.012 · Cited by 45
Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment
Tackley, G., O’Brien, F., Rocha, J., Woodhall, M. R., Waters, P. J., Chandratre, S., Halfpenny, C. A., Hemingway, C. A., Wassmer, E., Wasiewski, W. W., et al. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.02.014 · Cited by 44
Restoring immune tolerance in neuromyelitis optica: Part I
Steinman, L., Bar‐Or, A., Behne, J. M., Benítez‐Ribas, D., Chin, P. S., Clare-Salzler, M. J., Healey, D. G., Kim, J. I., Kranz, D. M., Lutterotti, A., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000276 · Cited by 43 · cited 1×
“Efforts to restore immune tolerance as novel therapeutic endeavor are in preparation, however, various technical and conceptual issues hamper prompt implementation in clinical trials and practice (248, 249).”
BackgroundSelf-citationFemale hormonal exposures and neuromyelitis optica symptom onset in a multicenter study
Bove, R. M., Elsone, L., Álvarez, E., Borisow, N., Cortez, M. M., Mateen, F. J., Mealy, M. A., Mutch, K., Tobyne, S. M., Ruprecht, K., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000339 · Cited by 43
Self-citationEvolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient
Asgari, N., Skejø, H. P. B., & Lennon, V. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318297ef07 · Cited by 43 · cited 1×
“They may not be present from relapse onset and may change into multiple short lesions or into spinal cord atrophy during the disease course (120, 121).”
BackgroundKira, J. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517703803 · Cited by 42
Martinez-Lapiscina, E. H., Sepulveda, M., Torres-Torres, R., Alba-Arbalat, S., Llufriu, S., Blanco, Y., Guerrero-Zamora, A. M., Sola-Valls, N., Ortiz-Perez, S., Villoslada, P., et al. (2016) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285616655264 · Cited by 41
Salmen, A., Hemmelmann, C., Starck, M., Zettl, U. K., Dörr, J., Paul, F., Flachenecker, P., Fleischer, V., Zipp, F., Nückel, H., et al. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611433318 · Cited by 40
Self-citationLong‐term MRI findings in neuromyelitis optica: seropositive versus seronegative patients
Kıyat-Atamer, A., Ekizoğlu, E., Tüzün, E., Kürtüncü, M., Shugaiv, E., Akman‐Demir, G., & Eraksoy, M. (2012) · European Journal of Neurology · doi:10.1111/ene.12058 · Cited by 40
Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple Sclerosis
Klawiter, E. C., Piccio, L. M., Lyons, J., Mikesell, R. J., O’Connor, K. C., & Cross, A. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.197 · Cited by 39
Immunoadsorption in patients with neuromyelitis optica spectrum disorder
Faissner, S., Nikolayczik, J., Chan, A., Gold, R., Yoon, M., & Haghikia, A. (2016) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285616646332 · Cited by 39
Cited by
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Self-citationRomán, G. C., Gracia, F., Torres, A., Palacios, A., Gracia, K., & Harris, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653786 · Cited by 237
Agasing, A. M., Wu, Q., Khatri, B., Borisow, N., Ruprecht, K., Brandt, A. U., Gawde, S., Kumar, G., Quinn, J. L., Ko, R. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16625-7 · Cited by 98
Self-citationDavé, V. A., & Klein, R. S. (2023) · Glia · doi:10.1002/glia.24294 · Cited by 29
“…(MRI) of patients that have recovered from WNV, including those without neuroinvasive disease, report atrophy of the posterior cingulate and insular cortices, and the hippocampus and entorhinal regions in the temporal lobe (Rev in Borisow et al., 2018), as observed in AD (Ledig et al., 2018).”
BackgroundLin, T.-Y., Chien, C., Lu, A., Paul, F., & Zimmermann, H. G. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1982697 · Cited by 16
Self-citation
Metadata
- Authors
- Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-23
- Volume
- 9
- Pages
- 888-888
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2895290943
- Cited by
- 227
- References
- 230
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.